MedPath

GlaxoSmithKline

GlaxoSmithKline logo
🇬🇧United Kingdom
Ownership
Public
Established
1929-01-01
Employees
70.2K
Market Cap
$90B
Website
http://www.gsk.com
Introduction

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

A Study to Evaluate the Effect of Itraconazole on the Concentration of GSK3923868 in the Blood in Healthy Participants

Phase 1
Not yet recruiting
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Drug: GSK3923868
Drug: Itraconazole
First Posted Date
2024-09-19
Last Posted Date
2024-09-19
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
20
Registration Number
NCT06597500
Locations
🇬🇧

GSK Investigational Site, Cambridge, United Kingdom

Safety, Tolerability and Blood Sampling of GSK3923868 Administered Via Dry Powder Inhaler to Healthy Participants of Chinese, Japanese and European Ancestry

Phase 1
Completed
Conditions
Respiratory Tract Infections
Interventions
Drug: GSK3923868
Drug: Placebo
First Posted Date
2024-08-29
Last Posted Date
2024-12-10
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
30
Registration Number
NCT06577597
Locations
🇬🇧

GSK Investigational Site, Middlesex, United Kingdom

A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants and Healthy Chinese and Japanese Participants

Phase 1
Recruiting
Conditions
Systemic Lupus Erythematosus
Interventions
Drug: GSK4527363
Drug: Placebo matching GSK4527363
Drug: Belimumab
First Posted Date
2024-08-28
Last Posted Date
2024-12-13
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
112
Registration Number
NCT06576271
Locations
🇬🇧

GSK Investigational Site, Cambridge, United Kingdom

A Study on the Safety of and Immune Response to Different Doses of an mRNA-based RSV Investigational Vaccine in Healthy Adults Aged 18-45 Years

Phase 1
Recruiting
Conditions
Respiratory Syncytial Virus Infections
Interventions
Biological: Investigational RSV vaccine 6
Biological: Investigational RSV vaccine 1
Biological: Investigational RSV vaccine 2
Biological: Investigational RSV vaccine 3
Biological: Investigational RSV vaccine 4
Biological: Investigational RSV vaccine 5
Drug: Placebo
First Posted Date
2024-08-27
Last Posted Date
2024-10-02
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
210
Registration Number
NCT06573281
Locations
🇪🇸

GSK Investigational Site, Madrid, Spain

A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease

Phase 3
Recruiting
Conditions
Lung Diseases, Interstitial
Interventions
Biological: Belimumab
Other: Placebo
First Posted Date
2024-08-27
Last Posted Date
2024-08-29
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
440
Registration Number
NCT06572384
Locations
🇪🇸

GSK Investigational Site, Sevilla, Spain

A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon Cancer

Phase 2
Not yet recruiting
Conditions
Neoplasms, Colon
Interventions
Biological: Dostarlimab
Drug: CAPEOX
First Posted Date
2024-08-23
Last Posted Date
2024-08-23
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
120
Registration Number
NCT06567782
Locations
🇬🇧

GSK Investigational Site, Sutton, United Kingdom

A Study on the Immune Response, Safety and the Occurrence of Respiratory Syncytial Virus (RSV)-Associated Respiratory Tract Illness After Administration of RSV OA Vaccine in Adults 60 Years and Older

Phase 3
Recruiting
Conditions
Respiratory Syncytial Virus Infections
Interventions
Biological: RSVPreF3 OA investigational vaccine
Drug: Placebo
First Posted Date
2024-08-13
Last Posted Date
2024-08-13
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
2600
Registration Number
NCT06551181
Locations
🇬🇧

GSK Investigational Site, Witney, United Kingdom

A Study of GSK5764227 in Participants With Advanced Solid Tumors

Phase 1
Recruiting
Conditions
Neoplasms
Interventions
Drug: GSK5764227
Drug: Topotecan
First Posted Date
2024-08-13
Last Posted Date
2024-11-28
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
240
Registration Number
NCT06551142
Locations
🇯🇵

GSK Investigational Site, Tokyo, Japan

A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)

Phase 2
Recruiting
Conditions
Chronic Hepatitis B Virus Infection
Hepatitis B
Interventions
Drug: Daplusiran/Tomligisiran Dose Level 1
Drug: Daplusiran/Tomligisiran Dose Level 2
Drug: Bepirovirsen
Drug: Placebo
First Posted Date
2024-08-05
Last Posted Date
2024-12-09
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
280
Registration Number
NCT06537414
Locations
🇬🇧

GSK Investigational Site, Middlesbrough, United Kingdom

An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study

Phase 3
Recruiting
Conditions
Respiratory Syncytial Virus Infections
Interventions
Biological: RSVPreF3 OA vaccine
First Posted Date
2024-08-02
Last Posted Date
2024-08-05
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
12000
Registration Number
NCT06534892
Locations
🇬🇧

GSK Investigational Site, Witney, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath